Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.
Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
